A human neutralizing monoclonal antibody DXP604 clinical emergency compassionate use project

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060488

Enrollment

Unknown

Registered

2022-06-03

Start date

2021-10-31

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus pneumonia(COVID-19)

Interventions

Experimental group:DXP604 injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Mild and ordinary patients with SARS-CoV-2 infection identified by PCR, including patients with associated high risk factors. High risk is defined as patients who meet at least one of the following criteria: (1) Aged >=65 years; (2) Chronic obstructive pulmonary disease/other chronic respiratory diseases.

Exclusion criteria

Exclusion criteria: 1. Allergic to any component of monoclonal antibody; 2. Pregnant patients; 3. The researchers think it is not suitable to participate; 4. Meningitis.

Design outcomes

Primary

Measure	Time frame
Virus clearance time;	—

Countries

China

Contacts

Public ContactJin Ronghua

93353503@qq.com+86 10 84322001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026